ArticleJournal of Cancer2018
Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer.
Article in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Suppression of NGALR impedes TNBC cell survival, proliferation, invasion, and migration through Akt/mTOR and JAK/STAT3 pathway inhibition.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Oncolytic Tanapoxvirus Recombinants Expressing Flagellin C or Mouse Interleukin-2 Are Capable of Regressing Human Triple-Negative Breast Cancer Xenografts in Immuno-Competent BALB/c Nude Mice.Pathogens (Basel, Switzerland) · 2024Article
- Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors.Medical oncology (Northwood, London, England) · 2023Review
- Article
- Review
- Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer.Frontiers in immunology · 2023Article
- Considerations of systemic treatment for matrix-producing carcinoma with curative intent.Gland surgery · 2022Article
- Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin.Science translational medicine · 2022Article
- Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.International journal of molecular sciences · 2022Article
- Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.International journal of molecular sciences · 2021Review
- Molecular Landscape of the Epithelial-Mesenchymal Transition in Endometrioid Endometrial Cancer.Journal of clinical medicine · 2021Article
- Prognostic Significance of CCNB2 Expression in Triple-Negative Breast Cancer.Cancer management and research · 2021Article
- Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.Cancer research · 2020Article
- Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.Breast cancer research and treatment · 2020Observational
- Epithelial-Mesenchymal Transition Proteins in Neuroendocrine Neoplasms: Differential Immunohistochemical Expression in Different Sites and Correlation with Clinico-Pathological Features.Diagnostics (Basel, Switzerland) · 2020Article
- Litchi Seed Aqueous Extracts play a role in suppression of epithelial-mesenchymal transition, invasion and migration in breast cancer cells.Cell cycle (Georgetown, Tex.) · 2020Article
- Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.International journal of nanomedicine · 2019Article
- Potential protein markers for breast cancer recurrence: a retrospective cohort study.Cancer causes & control : CCC · 2019Article
- Epithelial cell adhesion molecule and epithelial-mesenchymal transition are associated with vasculogenic mimicry, poor prognosis, and metastasis of triple negative breast cancer.International journal of clinical and experimental pathology · 2019Article
- Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1Journal of breast cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.